PKK Library

Your cart is empty.

Welcome to P K Kelkar Library, Online Public Access Catalogue (OPAC)

Normal view MARC view ISBD view

Aromatase Inhibitors

Contributor(s): Furr, Barrington J. A [editor.2] | SpringerLink (Online service)0.
Material type: materialTypeLabelBookSeries: Milestones in Drug Therapy0.Publisher: Basel : Birkh�user Basel, 2008. Edition: 2nd revised edition.Description: X, 189 p. online resource.Content type: text Media type: computer Carrier type: online resourceISBN: 9783764386931.Subject(s): Medicine | Cancer research | Pharmacology | Internal medicine | Oncology | Cell biology.1 | Biomedicine.2 | Cancer Research.2 | Pharmacology/Toxicology.2 | Oncology.2 | Internal Medicine.2 | Cell Biology.1DDC classification: 614.5999 Online resources: Click here to access online
Contents:
Background and development of aromatase inhibitors -- Aromatase inhibitors and models for breast cancer -- Clinical pharmacology of aromatase inhibitors -- Clinical studies with exemestane -- Clinical studies with letrozole -- Clinical studies with anastrozole -- The third-generation aromatase inhibitors: a clinical overview -- Lessons from the ArKO mouse -- Possible additional therapeutic uses of aromatase inhibitors.
In: Springer eBooks0Summary: Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.
    average rating: 0.0 (0 votes)
Item type Current location Call number Status Date due Barcode Item holds
PK Kelkar Library, IIT Kanpur
Available EBK4461
Total holds: 0

Background and development of aromatase inhibitors -- Aromatase inhibitors and models for breast cancer -- Clinical pharmacology of aromatase inhibitors -- Clinical studies with exemestane -- Clinical studies with letrozole -- Clinical studies with anastrozole -- The third-generation aromatase inhibitors: a clinical overview -- Lessons from the ArKO mouse -- Possible additional therapeutic uses of aromatase inhibitors.

Many breast tumours are dependent upon oestrogen for their development and continued growth. Over the last 25 years hormone therapy has progressed from the irreversible destruction of endocrine glands to the use of drugs that reversibly suppress oestrogen synthesis or action. The inhibition of oestrogen synthesis is most readily achieved by inhibiting the final step in the pathway of oestrogen biosynthesis, the reaction which transforms androgens into oestrogens by creating an aromatic ring in the steroid molecule (hence the enzyme's trivial name, aromatase). Whereas the first aromatase inhibitors to be used therapeutically could be shown to produce drug-induced inhibition of the enzyme and therapeutic benefits in patients with breast cancer, they were not particularly potent and lacked specificity. However, second-generation drugs were developed and most recently third-generation inhibitors have evolved which possess remarkable specificity and potency. Initial results from clinical trials suggest that these agents will become the cornerstones of future endocrine therapy.

There are no comments for this item.

Log in to your account to post a comment.

Powered by Koha